These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
61 related articles for article (PubMed ID: 184804)
41. A rapid method for screening inhibitor effects: determination of I50 and its standard deviation. Job D; Cochet C; Dhien A; Chambaz EM Anal Biochem; 1978 Jan; 84(1):68-77. PubMed ID: 204216 [No Abstract] [Full Text] [Related]
42. Attenuation of pulmonary leukocyte sequestration during extracorporeal circulation by a new c-AMP phosphodiesterase inhibitor. Ohtani M; Matsuda H; Shirakura R; Sawa Y; Matsuwaka R; Kuki S; Nakano S; Kawashima Y ASAIO Trans; 1988; 34(3):761-4. PubMed ID: 2848567 [TBL] [Abstract][Full Text] [Related]
43. Cardiac effects of menadione and its semiquinone. Carpenedo F; Floreani M; Santi Soncin E Cell Biol Int Rep; 1987 Jan; 11(1):63. PubMed ID: 3030570 [No Abstract] [Full Text] [Related]
44. Electrochemical evaluation of the interaction between ascorbic acid and the cardiotonic drug RS-82856. Visor GC; Lin LH; Kenley RA; Venuti MC; Alvarez R Drug Des Deliv; 1987 Dec; 2(2):121-8. PubMed ID: 2855568 [TBL] [Abstract][Full Text] [Related]
45. A potent and selective inhibitor of cyclic AMP phosphodiesterase with potential cardiotonic and antithrombotic properties. Alvarez R; Banerjee GL; Bruno JJ; Jones GL; Littschwager K; Strosberg AM; Venuti MC Mol Pharmacol; 1986 Jun; 29(6):554-60. PubMed ID: 3012320 [TBL] [Abstract][Full Text] [Related]
46. In vitro and in vivo myocardial effects of a cyclic AMP phosphodiesterase inhibitor structurally related to natural cardenolides. Prigent AF; Nemoz G; Roche M; Pacheco H Arch Int Pharmacodyn Ther; 1979 Sep; 241(1):131-52. PubMed ID: 230791 [TBL] [Abstract][Full Text] [Related]
47. Proceedings: Enhancement of ADP-induced platelet aggregation by isometric hand-grip excercise in sclerotic patients and its prevention by EG-626, cAMPPDE inhibitor. Sano T; Motimiya T; Yamazaki H; Shinamoto T Thromb Diath Haemorrh; 1975 Sep; 34(1):344. PubMed ID: 171796 [No Abstract] [Full Text] [Related]
48. Differential modulation of cytokine production by drugs: implications for therapy in heart failure. Matsumori A; Ono K; Sato Y; Shioi T; Nose Y; Sasayama S J Mol Cell Cardiol; 1996 Dec; 28(12):2491-9. PubMed ID: 9004165 [TBL] [Abstract][Full Text] [Related]
49. [Phosphodiesterase inhibition as a therapeutic principle]. Scholz H Z Kardiol; 1994; 83 Suppl 2():1-5. PubMed ID: 8091820 [TBL] [Abstract][Full Text] [Related]
50. Inotropic therapy of heart failure. Editorial comments on: Vasodilation and mechanoenergetic inefficiency dominates the effect of the "Ca2+ sensitizer" MCI-154 in intact pigs. Duncker DJ; Verdouw PD Scand Cardiovasc J; 2002 May; 36(3):131-5. PubMed ID: 12079634 [No Abstract] [Full Text] [Related]
51. Cardiovascular effects of UK 14,275: evaluation of a new phosphodiesterase inhibitor with inotropic properties in animals and human volunteers [proceedings]. Follath F; Kersting F; Lewis GR; Dollery CT Br J Clin Pharmacol; 1975 Aug; 2(4):372P-373P. PubMed ID: 184804 [No Abstract] [Full Text] [Related]
52. Demonstration of functional compartments of cyclic AMP in rat platelets by the use of phosphodiesterase inhibitors. Ashida S; Sakuma K Adv Second Messenger Phosphoprotein Res; 1992; 25():229-39. PubMed ID: 1313259 [No Abstract] [Full Text] [Related]